Rocket One (RKTO) Non-Current Deferred Tax Liability (2022)
Rocket One's (RKTO) quarterly Non-Current Deferred Tax Liability came in at $1.2 million in Q4 2022.
Analysis
Rocket One (RKTO) Non-Current Deferred Tax Liability (2022) Analysis & Trends
Rocket One has disclosed Non-Current Deferred Tax Liability across 1 years of filings, most recently posting $1.2 million for Q4 2022.
- In Q4 2022, Non-Current Deferred Tax Liability changed N/A year-over-year to $1.2 million; the TTM figure through Dec 2022 stood at $1.2 million (changed N/A YoY), while the FY2022 annual figure was $1.2 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability came in at $1.2 million for Q4 2022 at Rocket One.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.2 million in Q4 2022 to a low of $1.2 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Rocket One | 13.86 Mn | 5.97 Mn | - |